Effects of the 2016 CDC opioid prescribing guideline: a scoping review
Katherine E Warren, Sooyeon Kho, Carol Mita, Molly F Franke, Shelly F Greenfield, Scott G Weiner · 2026
Read Effects of the 2016 CDC opioid prescribing guideline: a scoping review by Katherine E Warren, Sooyeon Kho, Carol Mita, Molly F Franke, Shelly F Greenfield, Scott G Weiner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13239533.txt.
Description
Katherine E Warren and team review what followed a major American prescribing guide in a 2026 study. In March 2016 the Centers for Disease Control and Prevention issued advice on opioid drugs for chronic pain. The advice was voluntary, and the team gathered proof of its effects on patients, doctors, and health systems.
Ninety-four United States studies printed through 2025 met the bar for the review. Nearly all tracked prescribing, and almost every one found clear drops. The drops reached groups the guide never aimed at. Dose cuts for long-term users grew more common too. Few studies tracked how patients felt or whether effects were fair across groups. The authors call it a guide with both aimed reach and spill past its aims.
Catalog record
| CREATOR | Katherine E Warren, Sooyeon Kho, Carol Mita, Molly F Franke, Shelly F Greenfield, Scott G Weiner |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |